Cargando…
Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study – a cross-sectional study
OBJECTIVES: This study aims to determine the proportion of initial cardiometabolic assessment and its predicting factors in adults with schizophrenia, bipolar disorder or other related diagnoses for whom a second-generation antipsychotic was prescribed in the hospital setting. DESIGN: Cross-sectiona...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006820/ https://www.ncbi.nlm.nih.gov/pubmed/35414553 http://dx.doi.org/10.1136/bmjopen-2021-055454 |
_version_ | 1784686741050884096 |
---|---|
author | Fontaine, Jennifer Chin, Evelyn Provencher, Jean-François Rainone, Anthony Wazzan, Dana Roy, Carmella Rej, Soham Lordkipanidze, Marie Dagenais-Beaulé, Vincent |
author_facet | Fontaine, Jennifer Chin, Evelyn Provencher, Jean-François Rainone, Anthony Wazzan, Dana Roy, Carmella Rej, Soham Lordkipanidze, Marie Dagenais-Beaulé, Vincent |
author_sort | Fontaine, Jennifer |
collection | PubMed |
description | OBJECTIVES: This study aims to determine the proportion of initial cardiometabolic assessment and its predicting factors in adults with schizophrenia, bipolar disorder or other related diagnoses for whom a second-generation antipsychotic was prescribed in the hospital setting. DESIGN: Cross-sectional study. SETTING: The psychiatry unit of a Canadian tertiary care teaching hospital in Montreal, Canada. PARTICIPANTS: 402 patients with aforementioned disorders who initiated, restarted or switched to one of the following antipsychotics: clozapine, olanzapine, risperidone, paliperidone or quetiapine, between 2013 and 2016. PRIMARY OUTCOME MEASURES: We assessed the proportion of cardiometabolic parameters monitored. SECONDARY OUTCOME MEASURES: We identified predictors that influence the monitoring of cardiometabolic parameters and we assessed the proportion of adequate interventions following the screening of uncontrolled blood pressure and fasting glucose or glycated haemoglobin (HbA1c) results. RESULTS: Only 37.3% of patients received monitoring for at least three cardiometabolic parameters. Blood pressure was assessed in 99.8% of patients; lipid profile in 24.4%; fasting glucose or HbA1c in 33.3% and weight or body mass index in 97.8% of patients while waist circumference was assessed in 4.5% of patients. For patients with abnormal blood pressure and glycaemic values, 42.3% and 41.2% subsequent interventions were done, respectively. The study highlighted the psychiatric diagnosis (substance induced disorder OR 0.06 95% CI 0.00 to 0.44), the presence of a court-ordered treatment (OR 0.79 95% CI 0.35 to 1.79) and the treating psychiatrist (up to OR 34.0 95% CI 16.2 to 140.7) as predictors of cardiometabolic monitoring. CONCLUSIONS: This study reports suboptimal baseline cardiometabolic monitoring of patients taking an antipsychotic in a Canadian hospital. Optimising collaboration within a multidisciplinary team may increase cardiometabolic monitoring. |
format | Online Article Text |
id | pubmed-9006820 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-90068202022-05-02 Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study – a cross-sectional study Fontaine, Jennifer Chin, Evelyn Provencher, Jean-François Rainone, Anthony Wazzan, Dana Roy, Carmella Rej, Soham Lordkipanidze, Marie Dagenais-Beaulé, Vincent BMJ Open Cardiovascular Medicine OBJECTIVES: This study aims to determine the proportion of initial cardiometabolic assessment and its predicting factors in adults with schizophrenia, bipolar disorder or other related diagnoses for whom a second-generation antipsychotic was prescribed in the hospital setting. DESIGN: Cross-sectional study. SETTING: The psychiatry unit of a Canadian tertiary care teaching hospital in Montreal, Canada. PARTICIPANTS: 402 patients with aforementioned disorders who initiated, restarted or switched to one of the following antipsychotics: clozapine, olanzapine, risperidone, paliperidone or quetiapine, between 2013 and 2016. PRIMARY OUTCOME MEASURES: We assessed the proportion of cardiometabolic parameters monitored. SECONDARY OUTCOME MEASURES: We identified predictors that influence the monitoring of cardiometabolic parameters and we assessed the proportion of adequate interventions following the screening of uncontrolled blood pressure and fasting glucose or glycated haemoglobin (HbA1c) results. RESULTS: Only 37.3% of patients received monitoring for at least three cardiometabolic parameters. Blood pressure was assessed in 99.8% of patients; lipid profile in 24.4%; fasting glucose or HbA1c in 33.3% and weight or body mass index in 97.8% of patients while waist circumference was assessed in 4.5% of patients. For patients with abnormal blood pressure and glycaemic values, 42.3% and 41.2% subsequent interventions were done, respectively. The study highlighted the psychiatric diagnosis (substance induced disorder OR 0.06 95% CI 0.00 to 0.44), the presence of a court-ordered treatment (OR 0.79 95% CI 0.35 to 1.79) and the treating psychiatrist (up to OR 34.0 95% CI 16.2 to 140.7) as predictors of cardiometabolic monitoring. CONCLUSIONS: This study reports suboptimal baseline cardiometabolic monitoring of patients taking an antipsychotic in a Canadian hospital. Optimising collaboration within a multidisciplinary team may increase cardiometabolic monitoring. BMJ Publishing Group 2022-04-11 /pmc/articles/PMC9006820/ /pubmed/35414553 http://dx.doi.org/10.1136/bmjopen-2021-055454 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Cardiovascular Medicine Fontaine, Jennifer Chin, Evelyn Provencher, Jean-François Rainone, Anthony Wazzan, Dana Roy, Carmella Rej, Soham Lordkipanidze, Marie Dagenais-Beaulé, Vincent Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study – a cross-sectional study |
title | Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study – a cross-sectional study |
title_full | Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study – a cross-sectional study |
title_fullStr | Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study – a cross-sectional study |
title_full_unstemmed | Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study – a cross-sectional study |
title_short | Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study – a cross-sectional study |
title_sort | assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: the cami-sga study – a cross-sectional study |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006820/ https://www.ncbi.nlm.nih.gov/pubmed/35414553 http://dx.doi.org/10.1136/bmjopen-2021-055454 |
work_keys_str_mv | AT fontainejennifer assessingcardiometabolicparametermonitoringininpatientstakingasecondgenerationantipsychoticthecamisgastudyacrosssectionalstudy AT chinevelyn assessingcardiometabolicparametermonitoringininpatientstakingasecondgenerationantipsychoticthecamisgastudyacrosssectionalstudy AT provencherjeanfrancois assessingcardiometabolicparametermonitoringininpatientstakingasecondgenerationantipsychoticthecamisgastudyacrosssectionalstudy AT rainoneanthony assessingcardiometabolicparametermonitoringininpatientstakingasecondgenerationantipsychoticthecamisgastudyacrosssectionalstudy AT wazzandana assessingcardiometabolicparametermonitoringininpatientstakingasecondgenerationantipsychoticthecamisgastudyacrosssectionalstudy AT roycarmella assessingcardiometabolicparametermonitoringininpatientstakingasecondgenerationantipsychoticthecamisgastudyacrosssectionalstudy AT rejsoham assessingcardiometabolicparametermonitoringininpatientstakingasecondgenerationantipsychoticthecamisgastudyacrosssectionalstudy AT lordkipanidzemarie assessingcardiometabolicparametermonitoringininpatientstakingasecondgenerationantipsychoticthecamisgastudyacrosssectionalstudy AT dagenaisbeaulevincent assessingcardiometabolicparametermonitoringininpatientstakingasecondgenerationantipsychoticthecamisgastudyacrosssectionalstudy |